The "INSIGHT" trial: An explorative, open-labeled phase I study to evaluate the feasibility and safety of intra-tumoral, intra-peritoneal, and subcutaneous injections with IMP321 (LAG-3Ig fusion protein) for advanced stage solid tumor entities.

Daniel Wilhelm Mueller,Alexander Reichart,Salah-Eddin Al-Batran,Thorsten Oliver Goetze,Regina Eickhoff

doi:10.1200/jco.2018.36.15_suppl.tps3129

The "INSIGHT" trial: An explorative, open-labeled phase I study to evaluate the feasibility and safety of intra-tumoral, intra-peritoneal, and subcutaneous injections with IMP321 (LAG-3Ig fusion protein) for advanced stage solid tumor entities.

Daniel Wilhelm Mueller, Alexander Reichart + Show 3 more

https://doi.org/10.1200/jco.2018.36.15_suppl.tps3129

Copy DOI

Export

Save

Cite

Journal: Journal of Clinical Oncology

Publication Date: May 20, 2018

Affiliation: Krankenhaus Nordwest

#Advanced Stage Solid Tumor #LAG-3Ig Fusion Protein #Safety Of Injections #Intra-tumoral Injections #Open-labeled Phase #Treatment Of Solid Tumors #Subcutaneous Injections #Intra-peritoneal Injections #Advanced Solid Tumor #Treatment Of Tumors

Abstract
Full-Text
Similar Papers

Abstract

Listen

TPS3129Background: The INSIGHT study evaluates feasibility and safety of intratumoral and intraperitoneal injections of IMP321 (mono-agent) for the treatment of advanced stage solid tumors as well ...

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

The "INSIGHT" trial: An explorative, open-labeled phase I study to evaluate the feasibility and safety of intra-tumoral, intra-peritoneal, and subcutaneous injections with IMP321 (LAG-3Ig fusion protein) for advanced stage solid tumor entities.